CAR-T cell therapy to help highly sensitized kidney transplant patients
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a special immune cell treatment (CAR-T cells) can lower the antibodies that make it very hard for you to receive a kidney transplant. If it works, you might become eligible for a transplant sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old and have kidney failure requiring dialysis.
- You have a very high level of sensitization (cPRA of 99.5% or higher) and have been on the kidney transplant waiting list for at least a year.
- Your blood type is O or B, and you do not have a living donor or haven't been matched in a kidney swap program for 12 months.
- You are willing to stay within 2 hours of the study site for 28 days after the CAR-T cell infusion.
- You have had certain vaccines and test negative for tuberculosis, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special stem cell treatment (using your own stem cells) can reset your immune system so you can accept a kidney from a deceased donor, even if you have very high antibody levels that make it hard to find a match. It's for people who have been waiting a long time and haven't had a transplant offer.
This trial tests a new CAR-T therapy that targets immune cells to reduce harmful antibodies in highly sensitized kidney transplant candidates. The goal is to help your body accept a kidney from a donor that would otherwise be rejected.
This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.
This trial tests a new CAR-T cell treatment for children and adults with steroid-resistant nephrotic syndrome (SRNS), a kidney condition that doesn't get better with standard medicines. The goal is to see if this therapy can help improve kidney function when other treatments have failed.
This early-phase trial tests a new therapy that uses your own immune cells to reduce your body's attack on a new kidney. It aims to help people who are highly sensitized (hard to match) get a transplant successfully.
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.